Contact Us

CSL Biotherapies, and its parent company, CSL Limited have reached an agreement with Merck & Co., Inc. on rights to market and distribute Afluria^® in the United States under an exclusive, six-year agreement effective September 3, 2009. Merck has the exclusive right to sell and distribute Afluria^® in the United States beginning with the 2010-2011 influenza season. The manufacture, filling and packaging of Afluria^® will continue and will not change with this agreement; CSL Ltd. will retain the Afluria^® license.

For information on prebooking Afluria^® for the 2010-2011 season, please visit www.merckvaccines.com/afluria or call the Merck Vaccine Customer Center at 877-829-6372.

For any questions relating to Afluria^® 2009-2010, please contact 1-888-435-8633 or CustomerSupport@cslbiotherapies.com.

Afluria^® 2009-2010 Prescribing Information (Revised 11/2009)

CSL Biotherapies' plans or capacity for manufacturing and delivering its pandemic Influenza A (H1N1) Monovalent Vaccine to US Human Health Services (HHS) are not affected by the seasonal influenza vaccine agreement. For any questions relating to CSL Biotherapies' Influenza A (H1N1) 2009 Monovalent Vaccine, please contact 1-888-435-8633 or CustomerSupport@cslbiotherapies.com.

CSL Biotherapies' Influenza A (H1N1) 2009 Monovalent Vaccine Prescribing Information

Contact Us

Your feedback is appreciated!

We depend on your feedback to maintain a high-quality resource for information about Afluria^®. You may use the form below or contact us by telephone.

CSL Biotherapies
P.O. Box 60446
1020 First Avenue
King of Prussia, PA 19406 USA
1-888-4-FLU-OFF (1-888-435-8633)



To ensure that your question or comment is directed to the appropriate CSL Biotherapies department, please select one of these choices: *

I am a: *
First Name: *
Last Name: *
This is my: *	Home address Work address
Address 1: *
Address 2:
City: *
State: *
Zip: *
E-mail: *
Confirm E-mail: *
Telephone:
Fax:
Comments: *

I would like a CSL Biotherapies representative to contact me by: Phone Email

I would like to be contacted periodically with information about Afluria^® and special offers from CSL Biotherapies. Prior to submitting your information, please review our Privacy Policy.


* Required information

Important Safety Information

Afluria^® is indicated for active immunization of persons 18 years of age and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. The indication is based on the immune response elicited by Afluria^®; no controlled clinical studies have demonstrated a decrease in influenza disease after vaccination with Afluria^®.

Afluria^® should not be administered to individuals with hypersensitivity to eggs or chicken protein or other components of Afluria^®, or to anyone who has had a life-threatening reaction to previous influenza vaccination. The most common injection-site adverse reactions were tenderness, pain, redness, and swelling. The most common systemic adverse reactions were headache, malaise, and muscle aches.

Vaccination with Afluria^® may not protect all individuals. Immunocompromised persons may have a diminished immune response. If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give Afluria^® should be based on careful consideration of the potential benefits and risks.

Click here for full PRESCRIBING INFORMATION.

Order Afluria Now

Share with a Colleague

sign in | register | contact us | site map